Pulmonary Lesions Clinical Trial
Official title:
A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity
With the advent of CT screening for lung cancer, there is an increase in the detection of
pulmonary lesions with focal pure ground-glass opacity (pGGO). The pure Ground-glass
opacities can be caused by normal expiration, partial filling of air spaces, partial
collapse of alveoli, interstitial thickening, inflammation, oedema, fibrosis, and lepidic
proliferation of neoplasm. Precise details of the natural history of focal pure GGO are
still largely unclear. A number of differential diagnoses are possible, including
inflammatory disease, focal scar, atypical adenomatous hyperplasia (AAH), and adenocarcinoma
in situ. Some of pGGOs remained stable over a considerable time. A long doubling time for
pGGOs is already known. Therefore, the strategy of treatment for focal pure GGO lesions is
still undecided. The major issue is whether or not the doctors should treat these patients
at all or wait until the first sign of a solid lesion developes which may take many years.
The purpose of this study is to determine if the ablation therapy is safe and effective for
the pulmonary pGGO.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02146131 -
Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 )
|
N/A |